BrightGene Bio-medical Technology(SH:688166) Shang Hai Zheng Quan Bao·2025-11-03 20:05Core Viewpoint - The company, 博瑞生物医药 (Suzhou) Co., Ltd., has initiated a share repurchase program to utilize its own funds for buying back shares, which will be used for employee stock ownership plans or equity incentives in the future [1][3]. Summary by Sections 1. Share Repurchase Basic Information - On September 26, 2025, the company’s board approved a plan to repurchase shares through centralized bidding, with a maximum repurchase price of RMB 139.77 per share and a total fund allocation between RMB 10 million and RMB 20 million [1]. 2. Progress of Share Repurchase - As of October 31, 2025, the company has repurchased a total of 55,880 shares, representing 0.0132% of the total share capital of 423,102,473 shares. The highest and lowest prices for the repurchased shares were RMB 54.28 and RMB 52.96, respectively, with a total expenditure of RMB 2,993,933.37 (excluding transaction fees) [3]. 3. Other Matters - The company will adhere to relevant regulations during the repurchase period and will disclose information regarding the progress of the share repurchase in a timely manner [5].